OPEN END TURBO OPTIONSSCHEIN SHORT - BRISTOL-MYERS SQUIBB | Real-time Bid/Ask 13:24:30 24/06/2024 BST | ||
| 0.23 EUR / 0.24 EUR | -6.00% |
|
| Current month | -24.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24/06/24 | 0.24 | -4.00% |
| 21/06/24 | 0.25 | -21.88% |
| 20/06/24 | 0.32 | -5.88% |
| 19/06/24 | 0.34 | -2.86% |
| 18/06/24 | 0.35 | +6.06% |
Delayed Quote Börse Stuttgart
Last update June 24, 2024 at 09:05 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | Goldman Sachs |
| WKN | GG8FR5 |
| ISIN | DE000GG8FR54 |
| Date issued | 21/05/2024 |
| Strike | 44.53 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.11 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.4 € |
|---|---|
| Lowest since issue | 0.14 € |
| Spread | 0.01 € |
| Spread % | 4.17% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.93
USD
Average target price
53.19
USD
Spread / Average Target
+26.87%
- Stock Market
- Certificates
- Certificat
